Press Releases Feb 25, 2026 Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress Feb 19, 2026 Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Dec 12, 2025 U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents View all press releases Presentations & Events View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
Feb 25, 2026 Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Feb 19, 2026 Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Dec 12, 2025 U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents